| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/14/2009 | US20090123475 for isolation of DNA encoding anti-Rh(D) antibodies; isolation of DNA encoding antibodies directed against any red blood cells antigen or other cell antigen; for typing platelets by generating phage antibodies specific for a number of clinically important platelet antigens |
| 05/14/2009 | US20090123474 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| 05/14/2009 | US20090123472 Detection of mutations in a gene associated with resistance to viral infection, oas1 |
| 05/14/2009 | US20090123471 T-Cadherin antigen arrays and uses thereof |
| 05/14/2009 | US20090123470 Antibodies Against Cancer |
| 05/14/2009 | US20090123469 Anti-factor B antibodies and their uses |
| 05/14/2009 | US20090123468 Transducible polypeptides for modifying metabolism |
| 05/14/2009 | US20090123467 Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders |
| 05/14/2009 | US20090123466 Anti-cd40 monoclonal antibody |
| 05/14/2009 | US20090123465 Assessment of cardiac health and thrombotic risk in a patient |
| 05/14/2009 | US20090123464 Method for the potentiation of opioid analgesics effects on pain |
| 05/14/2009 | US20090123463 Methods and compositions for inducing apoptosis |
| 05/14/2009 | US20090123462 Fgfr agonists |
| 05/14/2009 | US20090123461 Human podocalyxin alternative-spliced forms and uses thereof |
| 05/14/2009 | US20090123460 Immunostimulatory combinations |
| 05/14/2009 | US20090123459 Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease |
| 05/14/2009 | US20090123458 having a modified histidine residue with a fluorine at the 2-position so that the pKa of the modified histidine residue is less than about 3; vaccine for the treatment of anthrax |
| 05/14/2009 | US20090123457 Lumican proteoglycan in the diagnosis and treatment of atherosclerosis |
| 05/14/2009 | US20090123456 determining whether an antibody is an agonist selective for nicotinic receptors, inhibits release of a proinflammatory cytokine from a mammalian cell, and if the antibody is reactive with nicotinic receptors; drug screening |
| 05/14/2009 | US20090123444 delivering a therapeutic agent to a solid tumor characterized by hypoxia, acidosis and hypertonicity comprising loading the therapeutic agent into sickle red blood cells; tissue targeted therapy; drug delivery |
| 05/14/2009 | US20090123438 Multivalent Vaccines Comprising Recombinant Viral Vectors |
| 05/14/2009 | US20090123427 Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in Same |
| 05/14/2009 | US20090123421 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| 05/14/2009 | US20090123420 Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase |
| 05/14/2009 | US20090123419 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/14/2009 | US20090123415 Diagnosis, treatment, and prevention of vascular disorders using il-1 autoantibodies |
| 05/14/2009 | US20090123414 Il-15 Antigen Arrays And Uses Thereof |
| 05/14/2009 | US20090123413 Use of bat monoclonal antibody for immunotherapy |
| 05/14/2009 | US20090123387 Buccal, polar and non-polar spray or capsule containing cardiovascular or reneal drugs |
| 05/14/2009 | US20090123382 Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| 05/14/2009 | US20090123378 Uses and compositions for treatment of ankylosing spondylitis |
| 05/14/2009 | US20090123376 Therapeutic agents with decreased toxicity |
| 05/14/2009 | US20090123375 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| 05/14/2009 | US20090123371 Molecular signature of cancer |
| 05/14/2009 | US20090123367 Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| 05/14/2009 | US20090123366 Targeted Therapy |
| 05/14/2009 | DE102007054049A1 System for drug transport into trypanosomal cells comprises a ktenate matrix with targeting molecules in the form of antibody Fc fragments |
| 05/14/2009 | CA2743032A1 Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n-glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes |
| 05/14/2009 | CA2706700A1 Compositions and methods for generating antibodies |
| 05/14/2009 | CA2705324A1 Immunogenic compositions capable of activating t-cells |
| 05/14/2009 | CA2705263A1 Uses of anti-cd40 antibodies |
| 05/14/2009 | CA2705242A1 Enhancement of immunogenicity of antigens |
| 05/14/2009 | CA2705152A1 Anti-vegf antibody compositions and methods |
| 05/14/2009 | CA2705105A1 Pharmaceutical composition for cancer treatment |
| 05/14/2009 | CA2705067A1 Increase of immune response and targeting by antigens and/or drug linkage |
| 05/14/2009 | CA2704974A1 Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| 05/14/2009 | CA2704775A1 Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine |
| 05/14/2009 | CA2704583A1 Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| 05/14/2009 | CA2704556A1 West nile virus vaccine, and method for production thereof |
| 05/14/2009 | CA2704232A1 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| 05/14/2009 | CA2703705A1 Methods of treating scleroderma |
| 05/14/2009 | CA2703099A1 Activin receptor-like kinase-i compositions and methods of use |
| 05/14/2009 | CA2702344A1 Analogues of glycolipids useful as immunoadjuvants |
| 05/13/2009 | EP2058408A2 Therapeutic GPCR targets in cancer |
| 05/13/2009 | EP2058399A1 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 05/13/2009 | EP2058395A1 Kif-derived peptide capable of binding to hla-a24 molecule |
| 05/13/2009 | EP2058334A2 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 05/13/2009 | EP2058333A2 Anti-CCR2 antibodies and methods of use therefor |
| 05/13/2009 | EP2058332A1 Use of CD25 binding molecules in steroid-resistant patients |
| 05/13/2009 | EP2058011A1 Nkt cell activating gycolipids covalently bound antigens and/or drug |
| 05/13/2009 | EP2058009A1 Reverse targeting lipid vesicle |
| 05/13/2009 | EP2058006A1 Anti-CCR5 antibody |
| 05/13/2009 | EP2058005A1 Inoculant for treating coeliac disease and method for producing the inoculant, application of a peptide sequence joined with a bacterial toxin for activating the immune system against prolamine and designer peptide |
| 05/13/2009 | EP2058004A1 Mannose immunogens for HIV-1 |
| 05/13/2009 | EP2058003A1 Medicaments and methods for treating mesothelioma |
| 05/13/2009 | EP2058002A1 Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
| 05/13/2009 | EP2058001A1 Enhancement of immunogenicity of antigens |
| 05/13/2009 | EP2058000A1 Immunogenic compositions capable of activating T cells |
| 05/13/2009 | EP2057999A2 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| 05/13/2009 | EP2057998A1 Use of modified cells for the treatment of multiple sclerosis |
| 05/13/2009 | EP2057466A2 Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy |
| 05/13/2009 | EP2057268A1 A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| 05/13/2009 | EP2057193A2 Ephb3-specific antibody and uses thereof |
| 05/13/2009 | EP2057190A2 Anti-interferon alpha monoclonal antibodies and methods for use |
| 05/13/2009 | EP2057186A2 Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens |
| 05/13/2009 | EP2056874A1 Tumor therapy with an anti-vegf antibody |
| 05/13/2009 | EP2056873A2 Methods and compositions for needleless delivery of particles |
| 05/13/2009 | EP2056872A2 Influenza hemagglutinin and neuraminidase variants |
| 05/13/2009 | EP2056871A2 Protein matrix vaccines and methods of making and administering such vaccines |
| 05/13/2009 | EP2056870A2 Trypanosome microsome system and uses thereof |
| 05/13/2009 | EP2056869A2 Dual variable domain immunoglobulin and uses thereof |
| 05/13/2009 | EP2056849A2 Methods and compositions for treating ige-mediated diseases |
| 05/13/2009 | EP2056838A2 Combination therapy for treatment of immune disorders |
| 05/13/2009 | EP1581759B1 Methods for treating taxol-induced sensory neuropathy |
| 05/13/2009 | EP1485477B1 Novel type-1 cytokine receptor glm-r |
| 05/13/2009 | EP1317536B1 Tnf receptor-like molecules and uses thereof |
| 05/13/2009 | EP1309692B1 Anti-il-12 antibodies, compositions, methods and uses |
| 05/13/2009 | EP1294891B1 Transport peptides derived from erns protein |
| 05/13/2009 | EP1115743B1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 05/13/2009 | EP1105498B1 Hiv vaccine |
| 05/13/2009 | EP0914325B1 Modulators of the function of fas receptors and other proteins |
| 05/13/2009 | EP0905140B9 Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use |
| 05/13/2009 | CN101433091A Method and formulation for transdermal delivery of immunologically active agents |
| 05/13/2009 | CN101432422A Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| 05/13/2009 | CN101432308A FAS binding antibodies |
| 05/13/2009 | CN101432307A Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 05/13/2009 | CN101432305A Transferrin receptor antibodies |
| 05/13/2009 | CN101432304A Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| 05/13/2009 | CN101432301A Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 05/13/2009 | CN101432298A PHL P1 allergen derivative |